Headache News and Research

Latest Headache News and Research

Migraine is a neurological, not vascular, disorder

The latest genetic and biological research shows that migraine is a neurological, not vascular, disorder and both acute and preventive treatments being developed target peripheral and central nervous systems, according to a prominent migraine expert addressing the American Pain Society (APS)today.

18 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Baxter International Inc. today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration.

From Baxter International Inc. 17 May 2012

Stroke survivors from King County to share their stories during EMS Week

Hours, or even minutes, can mean the difference between life and death when someone is having a stroke. As part of Emergency Medical Services (EMS) Week from May 20-26, stroke survivors from King County will share their stories about how quick recognition of stroke symptoms and timely response and treatment through King County EMS helps patients survive and return to full health.

17 May 2012

Dangerous, complex migraines linked to high risk for stroke

Nicole Soriano had headaches before but nothing like the one that struck in the middle of one summer night. A coincidence led nine days later to Cedars-Sinai Medical Center, where a rare type of migraine was diagnosed and treated - but any moment during that time could have been disastrous.

16 May 2012

Healthy lifestyle choices may reduce risk of stroke

Every 40 seconds someone in the United States has a stroke. Stroke is the fourth leading cause of death and the number one cause of adult disability in the country. While stroke often occurs without warning, understanding risk factors and learning to recognize symptoms can potentially save lives and limit damage if a stroke occurs. In recognition of National Stroke Awareness Month, Northwestern Medicine experts encourage consumers learn about their potential risk factors and start making lifestyle decisions that may decrease their likelihood of having a stroke.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

FDA ADAC recommends approval of Quad for HIV-1 infection

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.

14 May 2012

Even mild head injuries can cause abnormalities in brain function

Even mild head injuries can cause significant abnormalities in brain function that last for several days, which may explain the neurological symptoms experienced by some individuals who have experienced a head injury associated with sports, accidents or combat, according to a study by Virginia Commonwealth University School of Medicine researchers.

14 May 2012

Mild head injuries can cause structural disruption of axons in the brain

11 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

Caffeine consumption: How much is too much?

Chocolate, coffee and cola are perhaps three of your favourite consumables; however, they are also three caffeine-rich substances which all contribute to your daily caffeine consumption. According to the BBC, people should not exceed 400mg caffeine a day, and this limit halves for pregnant women, for which only 200mg/day is recommended.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Meningitis B vaccine on the horizon

Meningitis B is particularly dangerous for children, leading to 120 deaths in the UK every year. There are around 1,200 new cases of meningitis B every year. Around 1 in 10 victims die and another 15 per cent are left with permanent disabilities - often limbs have to be amputated due to blood poisoning. The infection causes inflammation of the membranes surrounding the spinal cord and brain. Symptoms include a severe headache, vomiting, a rash, sensitivity to light and a stiff neck.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012